{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:46:43Z","timestamp":1788612403230,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,7]]},"DOI":"10.7759\/cureus.43060","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T09:44:48Z","timestamp":1691401488000},"source":"Crossref","is-referenced-by-count":5,"title":["An Updated Systematic Review on Remdesivir\u2019s Safety and Efficacy in Patients Afflicted With COVID-19"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Yasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan Reddy","family":"Lankala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kalyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ishak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mekhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sestacovschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Kima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173926","article-title":"Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis","volume":"897","author":"Rezagholizadeh A","year":"2021","unstructured":"Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol. 2021, 897:173926. 10.1016\/j.ejphar.2021.173926","journal-title":"Eur J Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit E","year":"2020","unstructured":"de Wit E, Feldmann F, Cronin J, et al.. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020, 117:6771-6. 10.1073\/pnas.1922083117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan TP","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, et al.. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017, 9:10.1126\/scitranslmed.aal3653","journal-title":"Sci Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang M","year":"2020","unstructured":"Wang M, Cao R, Zhang L, et al.. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30:269-71. 10.1038\/s41422-020-0282-0","journal-title":"Cell Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110532","article-title":"Safety profile of the antiviral drug remdesivir: an update","volume":"130","author":"Fan Q","year":"2020","unstructured":"Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: an update. Biomed Pharmacother. 2020, 130:110532. 10.1016\/j.biopha.2020.110532","journal-title":"Biomed Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim K","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003, 73:712-6. 10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref10","unstructured":"Cochrane Collaboration. Review manager (RevMan) version 5.4. (2020). Accessed: September 27, 2022: https:\/\/training.cochrane.org\/online-learning\/core-software\/revman."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3071","article-title":"Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19","volume":"4","author":"Garibaldi BT","year":"2021","unstructured":"Garibaldi BT, Wang K, Robinson ML, et al.. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open. 2021, 4:e213071. 10.1001\/jamanetworkopen.2021.3071","journal-title":"JAMA Netw Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15735","article-title":"Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study","volume":"131","author":"Flisiak R","year":"2021","unstructured":"Flisiak R, Zar\u0119bska-Michaluk D, Berkan-Kawi\u0144ska A, et al.. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study. Pol Arch Intern Med. 2021, 131:103-10. 10.20452\/pamw.15735","journal-title":"Pol Arch Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_149_21","article-title":"Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study","volume":"65","author":"Mahajan L","year":"2021","unstructured":"Mahajan L, Singh AP, Gifty. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study. Indian J Anaesth. 2021, 65:S41-6. 10.4103\/ija.IJA_149_21","journal-title":"Indian J Anaesth"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner CD","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al.. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020, 324:1048-57. 10.1001\/jama.2020.16349","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104899","article-title":"Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status","volume":"158","author":"Antinori S","year":"2020","unstructured":"Antinori S, Cossu MV, Ridolfo AL, et al.. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020, 158:104899. 10.1016\/j.phrs.2020.104899","journal-title":"Pharmacol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","volume":"382","author":"Grein J","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, et al.. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020, 382:2327-36. 10.1056\/NEJMoa2007016","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa319","article-title":"Remdesivir use compared with supportive care in hospitalized patients with severe COVID-19: a single-center experience","volume":"7","author":"Kalligeros M","year":"2020","unstructured":"Kalligeros M, Tashima KT, Mylona EK, et al.. Remdesivir use compared with supportive care in hospitalized patients with severe COVID-19: a single-center experience. Open Forum Infect Dis. 2020, 7:ofaa319. 10.1093\/ofid\/ofaa319","journal-title":"Open Forum Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader F","year":"2022","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M, et al.. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022, 22:209-21. 10.1016\/S1473-3099(21)00485-0","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.12.05031","article-title":"Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment","volume":"12","author":"Polivka L","year":"2022","unstructured":"Polivka L, Gajdacsi J, Fazekas L, et al.. Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment. J Glob Health. 2022, 12:05031. 10.7189\/jogh.12.05031","journal-title":"J Glob Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali K","year":"2022","unstructured":"Ali K, Azher T, Baqi M, et al.. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022, 194:E242-51. 10.1503\/cmaj.211698","journal-title":"CMAJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19 - interim who Solidarity trial results","volume":"384","author":"Pan H","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al.. Repurposed antiviral drugs for COVID-19 - interim who Solidarity trial results. N Engl J Med. 2021, 384:497-511. 10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort","volume":"75","author":"Mozaffari E","year":"2022","unstructured":"Mozaffari E, Chandak A, Zhang Z, et al.. Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort. Clin Infect Dis. 2022, 75:e450-8. 10.1093\/cid\/ciab875","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2022.01.021","article-title":"Association of treatment with remdesivir and 30-day hospital readmissions in patients hospitalized with COVID-19","volume":"363","author":"Finn A","year":"2022","unstructured":"Finn A, Jindal A, Andrea SB, Selvaraj V, Dapaah-Afriyie K. Association of treatment with remdesivir and 30-day hospital readmissions in patients hospitalized with COVID-19. Am J Med Sci. 2022, 363:403-10. 10.1016\/j.amjms.2022.01.021","journal-title":"Am J Med Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020, 395:1569-78. 10.1016\/S0140-6736(20)31022-9","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.02.029","article-title":"A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel","volume":"27","author":"Goldberg E","year":"2021","unstructured":"Goldberg E, Ben Zvi H, Sheena L, Sofer S, Krause I, Sklan EH, Shlomai A. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel. Clin Microbiol Infect. 2021, 27:917.e1-4. 10.1016\/j.cmi.2021.02.029","journal-title":"Clin Microbiol Infect"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa321","article-title":"Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU","volume":"75","author":"Pasquini Z","year":"2020","unstructured":"Pasquini Z, Montalti R, Temperoni C, et al.. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J Antimicrob Chemother. 2020, 75:3359-65. 10.1093\/jac\/dkaa321","journal-title":"J Antimicrob Chemother"},{"key":"ref28","unstructured":"WHO R&D Blueprint. Novel coronavirus COVID-19 therapeutic trial synopsis. (2020). Accessed: September 27, 2022: https:\/\/www.who.int\/docs\/default-source\/blue-print\/covid-19-therapeutic-trial-synopsis."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40:373-83. 10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Lamontagne F","year":"2020","unstructured":"Lamontagne F, Agarwal A, Rochwerg B, et al.. A living WHO guideline on drugs for covid-19. BMJ. 2020, 370:m3379. 10.1136\/bmj.m3379","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19057-5","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"11","author":"Fajnzylber J","year":"2020","unstructured":"Fajnzylber J, Regan J, Coxen K, et al.. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020, 11:5493. 10.1038\/s41467-020-19057-5","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118663","article-title":"Remdesivir: a potential game-changer or just a myth? A systematic review and meta-analysis","volume":"264","author":"Shrestha DB","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Syed NI, Rawal E, Raut S, Khadka S. Remdesivir: a potential game-changer or just a myth? A systematic review and meta-analysis. Life Sci. 2021, 264:118663. 10.1016\/j.lfs.2020.118663","journal-title":"Life Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.15190\/d.2022.10","article-title":"Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children","volume":"10","author":"Chera A","year":"2022","unstructured":"Chera A, Tanca A. Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children. Discoveries (Craiova). 2022, 10:e151. 10.15190\/d.2022.10","journal-title":"Discoveries (Craiova)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa478","article-title":"Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj A","year":"2020","unstructured":"Bhimraj A, Morgan RL, Shumaker AH, et al.. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020, 10.1093\/cid\/ciaa478","journal-title":"Clin Infect Dis"},{"key":"ref35","unstructured":"ClinicalTrials.gov. Study of remdesivir in participants 18 years old and younger with COVID-19 (CARAVAN). (2020). Accessed: April 14, 2023: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04431453."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159660-an-updated-systematic-review-on-remdesivirs-safety-and-efficacy-in-patients-afflicted-with-covid-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:52Z","timestamp":1707508852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159660-an-updated-systematic-review-on-remdesivirs-safety-and-efficacy-in-patients-afflicted-with-covid-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.43060","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}